Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06244004 · ClinicalTrials.gov registry record · Phase 2
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
A Phase 2 study of Stage IVB Prostate Cancer AJCC v8 and Metastatic Prostate Carcinoma, sponsored by Northwestern University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
- 5
- Study locations
NCT06244004 is a Phase 2 study of Stage IVB Prostate Cancer AJCC v8 and Metastatic Prostate Carcinoma that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 125 participants, below the 174-participant average among 45 other Stage IVB Prostate Cancer AJCC v8 trials with a reported enrollment target (28% lower). The trial reports 5 study locations across 1 state.
The verdict
NCT06244004, a Phase 2 study of Stage IVB Prostate Cancer AJCC v8 and Metastatic Prostate Carcinoma, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
- 5
- Study locations
Study Summary
This phase II trial compares the effect of FDG-positron emission tomography (PET)-guided metastasis directed radiation therapy (MDRT) in combination with standard treatments to standard treatments alone in treating patients with prostate cancer that is sensitive to androgen-deprivation therapy (ADT) and has spread from where it first started (primary site) to other places in the body (metastatic). Prostate cancer is the second leading cause of cancer death among men in the United States, despite the approval of several life-prolonging treatments by the Food and Drug Administration. However, over the past 10 years, there have been significant improvements in prolonging the lives of those with metastatic hormone sensitive prostate cancer, specifically by adding treatments to standard therapy, such as ADT. More recently, trials have demonstrated a benefit of using radiotherapy (high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors) to delay the progression of cancer and prolong life for patients with metastatic disease. Imaging scans with FDG-PET may be able to identify cancer sites that remain active despite standard treatment. Giving MDRT plus standard treatment to patients with FDG-PET-identified cancer sites may work better than standard treatment alone in treating metastatic hormone sensitive prostate cancer.
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- PROCEDURE Bone Scan
- DRUG Antiandrogen Therapy
- PROCEDURE FDG-Positron Emission Tomography
- DRUG Cytotoxic Chemotherapy
Study Locations (5)
Illinois
- Northwestern University - Chicago
- Northwestern Medicine: Kishwaukee - DeKalb
- Northwestern Medicine: Delnor - Geneva
- Northwestern Medicine Orland Park - Orland Park
- Northwestern Medicine: Warrenville - Warrenville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2024-02-18 |
| Est. Completion | 2028-02-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06244004
The ClinicalTrials.gov registry entry for NCT06244004 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 174-participant average among 45 other Stage IVB Prostate Cancer AJCC v8 trials with a reported enrollment target (28% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Stage IVB Prostate Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.
NCT06244004 reports 5 study locations spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT06244004 about?
NCT06244004 is a clinical study titled "FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial". This phase II trial compares the effect of FDG-positron emission tomography (PET)-guided metastasis directed radiation therapy (MDRT) in combination with standard treatments to standard treatments alone in treating patients with prostate cancer that is sensitive to androgen-deprivation therapy (ADT)...
What is the current status of trial NCT06244004?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2024-02-18. Estimated completion is 2028-02-18.
What conditions does trial NCT06244004 study?
This clinical trial studies the following conditions: Stage IVB Prostate Cancer AJCC v8, Metastatic Prostate Carcinoma, Castration-Sensitive Prostate Carcinoma.
What interventions are being tested in trial NCT06244004?
The interventions under investigation include: Computed Tomography (PROCEDURE), Bone Scan (PROCEDURE), Antiandrogen Therapy (DRUG), FDG-Positron Emission Tomography (PROCEDURE), Cytotoxic Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT06244004?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06244004 being conducted?
This trial has 5 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IVB Prostate Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
RECRUITING · Phase 2
-
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
RECRUITING · Phase 2
-
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
RECRUITING · Phase 2
-
Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
RECRUITING · Phase 2
-
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 2
-
Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
RECRUITING · Phase 2
Explore more on PlainTrial
Stage IVB Prostate Cancer AJCC v8
All registered trials for this condition
Metastatic Prostate Carcinoma
All registered trials for this condition
Illinois
All trials with a study site in Illinois
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.